IDEX Reports Third Quarter Results;
Delivers Record Adjusted Gross and Operating Margin;
Reported EPS of $1.37 With Adjusted EPS of $1.52

LAKE FOREST, Ill.--()--IDEX Corporation (NYSE: IEX) today announced its financial results for the three month period ended September 30, 2019.

Third Quarter 2019 Highlights

  • Sales were flat overall and organically
  • Gross margin was 45.2 percent with adjusted gross margin of 45.7 percent, an all-time high
  • Reported operating margin was 22.7 percent with adjusted operating margin of 25.2 percent, up 120 bps
  • Reported EPS was $1.37 with adjusted EPS of $1.52, up 8 percent
  • Cash from operations of $157.1 million led to FCF of $146.0 million, an all-time high

Third Quarter 2019

Orders of $586.1 million were down 5 percent compared with the prior year period (-5 percent organic, +1 percent acquisitions and -1 percent foreign currency translation).

Sales of $624.2 million were flat compared with the prior year period (flat organic, +1 percent acquisitions and -1 percent foreign currency translation).

Gross margin of 45.2 percent was up 20 basis points compared with the prior year period. Excluding a $3.3 million pre-tax fair value inventory step-up charge related to the Velcora acquisition, adjusted gross margin of 45.7 percent was up 70 basis points primarily due to price and productivity initiatives, partially offset by higher engineering investments.

Operating income of $141.8 million resulted in an operating margin of 22.7 percent. Excluding the $3.3 million fair value inventory step-up charge and $12.0 million of restructuring expenses, adjusted operating income was $157.1 million with an adjusted operating margin of 25.2 percent, up 120 basis points compared with the adjusted prior year period primarily due to gross margin expansion and lower variable compensation costs as well as an overall tighter cost control environment. Adjusted operating income drove adjusted EBITDA of $175.4 million which was 28 percent of sales and covered interest expense by over 15 times.

Provision for income taxes of $24.0 million in the third quarter of 2019 resulted in an effective tax rate (ETR) of 18.6 percent, which was lower than the prior year period ETR of 20.2 percent primarily due to a change in U.S. Treasury regulations as well as the mix of global pre-tax income among jurisdictions. The third quarter 2019 ETR of 18.6 percent was lower than our previously guided ETR of 22.5 percent, which provided 6 cents of EPS favorability. This was primarily due to higher excess tax benefits from greater than expected stock option exercises in the third quarter of 2019 as well as a favorable impact from the 2018 income tax return-to-provision adjustment.

Net income was $105.2 million which resulted in EPS of $1.37. Excluding the fair value inventory step-up charge and restructuring expenses, adjusted EPS was $1.52, an increase of 11 cents, or 8 percent, from the adjusted prior year period EPS.

Cash from operations of $157.1 million led to free cash flow of $146.0 million, which was up 28 percent from the prior year period and 125 percent of adjusted net income. The increase in free cash flow was primarily due to favorable operating working capital and lower capital expenditures in the third quarter of 2019.

“The third quarter was all about operational execution which allowed us to expand both gross and operating margins to all-time highs. Adjusted gross margin of 45.7 percent and adjusted operating margin of 25.2 percent were up 70 and 120 basis points, respectively. This margin expansion helped us deliver record adjusted EPS of $1.52. Free cash flow was strong with a conversion rate of 125 percent of adjusted net income, up 28 percent from the prior year period. On the commercial side, demand was challenging in the third quarter due to the continued softening of the global economy. The unresolved trade conflicts continued to weigh on global growth in most of our end markets, as companies are delaying investments due to the unclear outlook. As a result, organic sales in the third quarter were flat compared to the prior year period. However, I am very pleased with how the team performed in this challenging environment and confident that we will keep delivering strong operating results during these volatile times.

 

M&A continues to be a key priority of the Company. In July, we acquired Velcora and are currently in the process of integrating its operations into our existing Sealing Solutions platform within the Health & Science Technologies segment. We have approximately $2 billion of capacity to support additional opportunities based on existing cash, availability under our revolver and a low debt leverage ratio.

 

Based on recent order trends and instability within the macro-economic environment, we now project approximately 2 percent organic revenue growth for 2019, with flat organic sales in the fourth quarter. We have narrowed full year 2019 adjusted EPS to $5.80 to $5.82, with fourth quarter EPS of $1.33 to $1.35.”

 

 

Andrew K. Silvernail

 

Chairman and Chief Executive Officer

Third Quarter 2019 Segment Highlights

Fluid & Metering Technologies

  • Sales of $240.9 million reflected a 1 percent increase compared to the third quarter of 2018 (+2 percent organic and -1 percent foreign currency translation).
  • Operating income of $77.5 million resulted in an operating margin of 32.2 percent, a 270 basis point increase compared to the adjusted prior year period primarily due to price and productivity initiatives, partially offset by higher engineering investments.
  • EBITDA of $82.7 million resulted in an EBITDA margin of 34.3 percent, a 270 basis point increase compared to the adjusted prior year period primarily due to increased operating income.

Health & Science Technologies

  • Sales of $229.6 million reflected a 3 percent increase compared to the third quarter of 2018 (+1 percent organic, +3 percent acquisition and -1 percent foreign currency translation).
  • Operating income of $40.2 million resulted in an operating margin of 17.5 percent. Excluding the $3.3 million fair value inventory step-up charge and $11.2 million of restructuring expenses, adjusted operating income was $54.7 million with an adjusted operating margin of 23.8 percent, a 30 basis point increase compared to the adjusted prior year period primarily due to higher volume and price, partially offset by higher engineering investments and increased amortization due to the acquisition.
  • EBITDA of $49.2 million resulted in an EBITDA margin of 21.4 percent. Excluding the $3.3 million fair value inventory step-up charge and $11.2 million of restructuring expenses, adjusted EBITDA of $63.7 million resulted in an adjusted EBITDA margin of 27.8 percent, a 40 basis point increase compared to the adjusted prior year period primarily due to increased operating income.

Fire & Safety/Diversified Products

  • Sales of $154.5 million reflected a 5 percent decrease compared to the third quarter of 2018 (-3 percent organic and -2 percent foreign currency translation) mainly attributable to large project orders within our dispensing and fire businesses in the prior year period not repeating.
  • Operating income of $42.0 million resulted in an operating margin of 27.2 percent. Excluding $0.1 million of restructuring expenses, adjusted operating income was $42.1 million with an adjusted operating margin of 27.2 percent, a 50 basis point decrease compared to the adjusted prior year period primarily due to reduced volume.
  • EBITDA of $45.6 million resulted in an EBITDA margin of 29.5 percent. Excluding $0.1 million of restructuring expenses, adjusted EBITDA of $45.7 million resulted in an adjusted EBITDA margin of 29.6 percent, a 10 basis point decrease compared to the adjusted prior year period primarily due to a decrease in operating income.

For the third quarter of 2019, Fluid & Metering Technologies contributed 38 percent of sales, 49 percent of operating income and 47 percent of EBITDA; Health & Science Technologies accounted for 37 percent of sales, 25 percent of operating income and 28 percent of EBITDA; and Fire & Safety/Diversified Products represented 25 percent of sales, 26 percent of operating income and 25 percent of EBITDA.

Acquisition

In July 2019, the Company acquired Velcora Holding AB and its operating subsidiaries, Roplan and Steridose. Roplan is a global manufacturer of custom mechanical and shaft seals for a variety of end markets including food & beverage, marine, chemical, wastewater and water treatment. Steridose develops engineered hygienic mixers and valves for the global biopharmaceutical industry. With annual revenue of approximately $40 million, both businesses operate within the Health & Science Technologies segment. In connection with this acquisition, the Company had to write up inventory to its fair value which resulted in a $3.3 million fair value inventory step-up charge in the quarter.

Restructuring Actions

The Company recorded $12.0 million and $14.1 million of restructuring expenses in the third quarter and nine months ended September 30, 2019, respectively, as part of initiatives that supported the implementation of key strategic efforts designed to facilitate long-term, sustainable growth through cost reduction actions, primarily consisting of employee reductions, facility rationalization and impairment charges. These restructuring actions included a $9.7 million impairment charge in the third quarter related to the winding down of a business within the Health & Science Technologies segment.

Non-U.S. GAAP Measures of Financial Performance

The Company supplements certain U.S. GAAP financial performance metrics with non-U.S. GAAP financial performance metrics in order to provide investors with better insight and increased transparency while also allowing for a more comprehensive understanding of the financial information used by management in its decision making. Reconciliations of non-U.S. GAAP financial performance metrics to their most comparable U.S. GAAP financial performance metrics are defined and presented below and should not be considered a substitute for, nor superior to, the financial data prepared in accordance with U.S. GAAP. There were no adjustments to U.S. GAAP financial performance metrics other than the items noted below.

  • Organic orders and sales are calculated excluding amounts from acquired or divested businesses during the first twelve months of ownership or divestiture and the impact of foreign currency translation.
  • Adjusted gross margin is calculated as gross margin plus the fair value inventory step-up charge.
  • Adjusted operating income is calculated as operating income plus the fair value inventory step-up charge plus restructuring expenses.
  • Adjusted operating margin is calculated as adjusted operating income divided by net sales.
  • Adjusted net income is calculated as net income plus the fair value inventory step-up charge plus restructuring expenses, net of the statutory tax expense or benefit.
  • EBITDA is calculated as net income plus interest expense plus provision for income taxes plus depreciation and amortization. We reconciled EBITDA to net income on a consolidated basis as we do not allocate consolidated interest expense or consolidated provision for income taxes to our segments.
  • Adjusted EBITDA is calculated as EBITDA plus the fair value inventory step-up charge plus restructuring expenses.
  • Free cash flow is calculated as cash flow from operating activities less capital expenditures.

Table 1: Reconciliations of the Change in Net Sales to Organic Net Sales

 

Three Months Ended September 30, 2019

 

Nine Months Ended September 30, 2019

 

FMT

 

HST

 

FSDP

 

IDEX

 

FMT

 

HST

 

FSDP

 

IDEX

Change in net sales

1

%

 

3

%

 

(5

)%

 

%

 

2

%

 

2

%

 

(2

)%

 

1

%

- Net impact from acquisitions

%

 

3

%

 

%

 

1

%

 

%

 

2

%

 

%

 

1

%

- Impact from FX

(1

)%

 

(1

)%

 

(2

)%

 

(1

)%

 

(2

)%

 

(2

)%

 

(2

)%

 

(2

)%

Change in organic net sales

2

%

 

1

%

 

(3

)%

 

%

 

4

%

 

2

%

 

%

 

2

%

Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Margin (dollars in thousands)

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2019

 

2018

 

2019

 

2018

Gross profit

$

281,978

 

 

$

280,233

 

 

$

858,149

 

 

$

844,252

 

+ Fair value inventory step-up charge

3,340

 

 

 

 

3,340

 

 

 

Adjusted gross profit

$

285,318

 

 

$

280,233

 

 

$

861,489

 

 

$

844,252

 

 

 

 

 

 

 

 

 

Net sales

$

624,246

 

 

$

622,888

 

 

$

1,888,576

 

 

$

1,869,572

 

 

 

 

 

 

 

 

 

Gross profit margin

45.2

%

 

45.0

%

 

45.4

%

 

45.2

%

Adjusted gross profit margin

45.7

%

 

45.0

%

 

45.6

%

 

45.2

%

Table 3: Reconciliations of Reported-to-Adjusted Operating Income and Margin (dollars in thousands)

 

Three Months Ended September 30,

 

2019

 

2018

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

Reported operating income (loss)

$

77,481

 

 

$

40,170

 

 

$

41,967

 

 

$

(17,853

)

 

$

141,765

 

 

$

69,755

 

 

$

49,144

 

 

$

44,726

 

 

$

(18,492

)

 

$

145,133

 

+ Restructuring expenses

 

 

11,196

 

 

104

 

 

656

 

 

11,956

 

 

827

 

 

3,116

 

 

60

 

 

618

 

 

4,621

 

+ Fair value inventory step-up charge

 

 

3,340

 

 

 

 

 

 

3,340

 

 

 

 

 

 

 

 

 

 

 

Adjusted operating income (loss)

$

77,481

 

 

$

54,706

 

 

$

42,071

 

 

$

(17,197

)

 

$

157,061

 

 

$

70,582

 

 

$

52,260

 

 

$

44,786

 

 

$

(17,874

)

 

$

149,754

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales (eliminations)

$

240,861

 

 

$

229,610

 

 

$

154,543

 

 

$

(768

)

 

$

624,246

 

 

$

239,213

 

 

$

222,426

 

 

$

161,832

 

 

$

(583

)

 

$

622,888

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported operating margin

32.2

%

 

17.5

%

 

27.2

%

 

n/m

 

22.7

%

 

29.2

%

 

22.1

%

 

27.6

%

 

n/m

 

23.3

%

Adjusted operating margin

32.2

%

 

23.8

%

 

27.2

%

 

n/m

 

25.2

%

 

29.5

%

 

23.5

%

 

27.7

%

 

n/m

 

24.0

%

 

Nine Months Ended September 30,

 

2019

 

2018

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

Reported operating income (loss)

$

223,493

 

 

$

151,087

 

 

$

125,909

 

 

$

(55,659

)

 

$

444,830

 

 

$

207,149

 

 

$

153,519

 

 

$

130,162

 

 

$

(61,183

)

 

$

429,647

 

+ Restructuring expenses

930

 

 

11,526

 

 

923

 

 

703

 

 

14,082

 

 

1,313

 

 

5,298

 

 

427

 

 

1,213

 

 

8,251

 

+ Fair value inventory step-up charge

 

 

3,340

 

 

 

 

 

 

3,340

 

 

 

 

 

 

 

 

 

 

 

Adjusted operating income (loss)

$

224,423

 

 

$

165,953

 

 

$

126,832

 

 

$

(54,956

)

 

$

462,252

 

 

$

208,462

 

 

$

158,817

 

 

$

130,589

 

 

$

(59,970

)

 

$

437,898

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales (eliminations)

$

729,572

 

 

$

687,153

 

 

$

474,745

 

 

$

(2,894

)

 

$

1,888,576

 

 

$

714,346

 

 

$

670,904

 

 

$

485,305

 

 

$

(983

)

 

$

1,869,572

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported operating margin

30.6

%

 

22.0

%

 

26.5

%

 

n/m

 

23.6

%

 

29.0

%

 

22.9

%

 

26.8

%

 

n/m

 

23.0

%

Adjusted operating margin

30.8

%

 

24.2

%

 

26.7

%

 

n/m

 

24.5

%

 

29.2

%

 

23.7

%

 

26.9

%

 

n/m

 

23.4

%

Table 4: Reconciliations of Reported-to-Adjusted Net Income and EPS (in thousands, except EPS)

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2019

 

2018

 

2019

 

2018

Reported net income

$

105,194

 

 

$

106,352

 

 

$

328,671

 

 

$

312,436

 

+ Restructuring expenses

11,956

 

 

4,621

 

 

14,082

 

 

8,251

 

+ Tax impact on restructuring expenses

(2,776

)

 

(1,130

)

 

(3,336

)

 

(2,003

)

+ Fair value inventory step-up charge

3,340

 

 

 

 

3,340

 

 

 

+ Tax impact on fair value inventory step-up charge

(735

)

 

 

 

(735

)

 

 

Adjusted net income

$

116,979

 

 

$

109,843

 

 

$

342,022

 

 

$

318,684

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2019

 

2018

 

2019

 

2018

Reported diluted EPS

$

1.37

 

 

$

1.37

 

 

$

4.30

 

 

$

4.02

 

+ Restructuring expenses

0.16

 

 

0.06

 

 

0.18

 

 

0.11

 

+ Tax impact on restructuring expenses

(0.04

)

 

(0.02

)

 

(0.04

)

 

(0.03

)

+ Fair value inventory step-up charge

0.04

 

 

 

 

0.04

 

 

 

+ Tax impact on fair value inventory step-up charge

(0.01

)

 

 

 

(0.01

)

 

 

Adjusted diluted EPS

$

1.52

 

 

$

1.41

 

 

$

4.47

 

 

$

4.10

 

 

 

 

 

 

 

 

 

Diluted weighted average shares outstanding

76,577

 

 

77,709

 

 

76,415

 

 

77,717

 

Table 5: Reconciliations of EBITDA to Net Income (dollars in thousands)

 

Three Months Ended September 30,

 

2019

 

2018

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

Reported operating income (loss)

$

77,481

 

 

$

40,170

 

 

$

41,967

 

 

$

(17,853

)

 

$

141,765

 

 

$

69,755

 

 

$

49,144

 

 

$

44,726

 

 

$

(18,492

)

 

$

145,133

 

- Other (income) expense - net

295

 

 

1,272

 

 

(92

)

 

(256

)

 

1,219

 

 

411

 

 

780

 

 

342

 

 

(599

)

 

934

 

+ Depreciation and amortization

5,507

 

 

10,296

 

 

3,566

 

 

154

 

 

19,523

 

 

5,500

 

 

9,381

 

 

3,541

 

 

184

 

 

18,606

 

EBITDA

82,693

 

 

49,194

 

 

45,625

 

 

(17,443

)

 

160,069

 

 

74,844

 

 

57,745

 

 

47,925

 

 

(17,709

)

 

162,805

 

- Interest expense

 

 

 

 

 

 

 

 

11,330

 

 

 

 

 

 

 

 

 

 

10,958

 

- Provision for income taxes

 

 

 

 

 

 

 

 

24,022

 

 

 

 

 

 

 

 

 

 

26,889

 

- Depreciation and amortization

 

 

 

 

 

 

 

 

19,523

 

 

 

 

 

 

 

 

 

 

18,606

 

Reported net income

 

 

 

 

 

 

 

 

$

105,194

 

 

 

 

 

 

 

 

 

 

$

106,352

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales (eliminations)

$

240,861

 

 

$

229,610

 

 

$

154,543

 

 

$

(768

)

 

$

624,246

 

 

$

239,213

 

 

$

222,426

 

 

$

161,832

 

 

$

(583

)

 

$

622,888

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported operating margin

32.2

%

 

17.5

%

 

27.2

%

 

n/m

 

22.7

%

 

29.2

%

 

22.1

%

 

27.6

%

 

n/m

 

23.3

%

EBITDA margin

34.3

%

 

21.4

%

 

29.5

%

 

n/m

 

25.6

%

 

31.3

%

 

26.0

%

 

29.6

%

 

n/m

 

26.1

%

 

Nine Months Ended September 30,

 

2019

 

2018

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

Reported operating income (loss)

$

223,493

 

 

$

151,087

 

 

$

125,909

 

 

$

(55,659

)

 

$

444,830

 

 

$

207,149

 

 

$

153,519

 

 

$

130,162

 

 

$

(61,183

)

 

$

429,647

 

- Other (income) expense - net

612

 

 

1,636

 

 

273

 

 

(1,820

)

 

701

 

 

1,056

 

 

(280

)

 

(3,324

)

 

(1,017

)

 

(3,565

)

+ Depreciation and amortization

16,653

 

 

29,438

 

 

10,745

 

 

510

 

 

57,346

 

 

16,901

 

 

30,860

 

 

10,912

 

 

557

 

 

59,230

 

EBITDA

239,534

 

 

178,889

 

 

136,381

 

 

(53,329

)

 

501,475

 

 

222,994

 

 

184,659

 

 

144,398

 

 

(59,609

)

 

492,442

 

- Interest expense

 

 

 

 

 

 

 

 

33,262

 

 

 

 

 

 

 

 

 

 

33,098

 

- Provision for income taxes

 

 

 

 

 

 

 

 

82,196

 

 

 

 

 

 

 

 

 

 

87,678

 

- Depreciation and amortization

 

 

 

 

 

 

 

 

57,346

 

 

 

 

 

 

 

 

 

 

59,230

 

Reported net income

 

 

 

 

 

 

 

 

$

328,671

 

 

 

 

 

 

 

 

 

 

$

312,436

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales (eliminations)

$

729,572

 

 

$

687,153

 

 

$

474,745

 

 

$

(2,894

)

 

$

1,888,576

 

 

$

714,346

 

 

$

670,904

 

 

$

485,305

 

 

$

(983

)

 

$

1,869,572

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported operating margin

30.6

%

 

22.0

%

 

26.5

%

 

n/m

 

23.6

%

 

29.0

%

 

22.9

%

 

26.8

%

 

n/m

 

23.0

%

EBITDA margin

32.8

%

 

26.0

%

 

28.7

%

 

n/m

 

26.6

%

 

31.2

%

 

27.5

%

 

29.8

%

 

n/m

 

26.3

%

Table 6: Reconciliations of EBITDA to Adjusted EBITDA (dollars in thousands)

 

Three Months Ended September 30,

 

2019

 

2018

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

EBITDA

$

82,693

 

 

$

49,194

 

 

$

45,625

 

 

$

(17,443

)

 

$

160,069

 

 

$

74,844

 

 

$

57,745

 

 

$

47,925

 

 

$

(17,709

)

 

$

162,805

 

+ Restructuring expenses

 

 

11,196

 

 

104

 

 

656

 

 

11,956

 

 

827

 

 

3,116

 

 

60

 

 

618

 

 

4,621

 

+ Fair value inventory step-up charge

 

 

3,340

 

 

 

 

 

 

3,340

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

$

82,693

 

 

$

63,730

 

 

$

45,729

 

 

$

(16,787

)

 

$

175,365

 

 

$

75,671

 

 

$

60,861

 

 

$

47,985

 

 

$

(17,091

)

 

$

167,426

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margin

34.3

%

 

27.8

%

 

29.6

%

 

n/m

 

28.1

%

 

31.6

%

 

27.4

%

 

29.7

%

 

n/m

 

26.9

%

 

Nine Months Ended September 30,

 

2019

 

2018

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

 

FMT

 

HST

 

FSDP

 

Corporate

 

IDEX

EBITDA

$

239,534

 

 

$

178,889

 

 

$

136,381

 

 

$

(53,329

)

 

$

501,475

 

 

$

222,994

 

 

$

184,659

 

 

$

144,398

 

 

$

(59,609

)

 

$

492,442

 

+ Restructuring expenses

930

 

 

11,526

 

 

923

 

 

703

 

 

14,082

 

 

1,313

 

 

5,298

 

 

427

 

 

1,213

 

 

8,251

 

+ Fair value inventory step-up charge

 

 

3,340

 

 

 

 

 

 

3,340

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

$

240,464

 

 

$

193,755

 

 

$

137,304

 

 

$

(52,626

)

 

$

518,897

 

 

$

224,307

 

 

$

189,957

 

 

$

144,825

 

 

$

(58,396

)

 

$

500,693

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margin

33.0

%

 

28.2

%

 

28.9

%

 

n/m

 

27.5

%

 

31.4

%

 

28.3

%

 

29.8

%

 

n/m

 

26.8

%

Table 7: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (in thousands)

 

Three Months Ended

 

Nine Months Ended

 

September 30,

 

June 30,

 

September 30,

 

2019

 

2018

 

2019

 

2019

 

2018

Cash flows from operating activities

$

157,064

 

 

$

133,327

 

 

$

131,175

 

 

$

376,902

 

 

$

325,753

 

- Capital expenditures

11,031

 

 

18,888

 

 

12,867

 

 

36,773

 

 

39,856

 

Free cash flow

$

146,033

 

 

$

114,439

 

 

$

118,308

 

 

$

340,129

 

 

$

285,897

 

Conference Call to be Broadcast over the Internet

IDEX will broadcast its third quarter earnings conference call over the Internet on Wednesday, October 30, 2019 at 9:30 a.m. CT. Chairman and Chief Executive Officer Andy Silvernail and Senior Vice President and Chief Financial Officer William Grogan will discuss the Company’s recent financial performance and respond to questions from the financial analyst community. IDEX invites interested investors to listen to the call and view the accompanying slide presentation, which will be carried live on its website at www.idexcorp.com. Those who wish to participate should log on several minutes before the discussion begins. After clicking on the presentation icon, investors should follow the instructions to ensure their systems are set up to hear the event and view the presentation slides, or download the correct applications at no charge. Investors will also be able to hear a replay of the call by dialing 877.660.6853 (or 201.612.7415 for international participants) using the ID #13684164.

Forward-Looking Statements

This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the Company believes,” “the Company intends,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release. The risks and uncertainties include, but are not limited to, the following: economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company's results, particularly in light of the low levels of order backlogs it typically maintains; the Company's ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K filed with the SEC and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this news release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

About IDEX

IDEX (NYSE: IEX) is a company that has undoubtedly touched your life in some way. In fact, IDEX businesses make thousands of products that are mission-critical components in everyday activities. Chances are the car you’re driving has a BAND-IT® clamp holding your side airbag safely in place. If you were ever in a car accident, a Hurst Jaws of Life® rescue tool may have saved your life. If you or a family member is battling cancer, your doctor may have tested your DNA in a quest to find the best targeted medicine for you. It’s likely your DNA test was run on equipment that contains components made by our growing IDEX Health & Science team. Founded in 1988 with three small, entrepreneurial manufacturing companies, we’re proud to say that we now call 40 diverse businesses around the world part of the IDEX family. With 7,000 employees and manufacturing operations in more than 20 countries, IDEX is a high-performing, global $2+ billion company committed to making trusted solutions that improve lives. IDEX shares are traded on the New York Stock Exchange under the symbol “IEX”.

For further information on IDEX Corporation and its business units, visit the company’s website at www.idexcorp.com.

(Financial reports follow)

 

IDEX CORPORATION

Condensed Consolidated Statements of Operations

(in thousands except per share amounts)

(unaudited)

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

2019

 

2018

 

2019

 

2018

Net sales

$

624,246

 

 

$

622,888

 

 

$

1,888,576

 

 

$

1,869,572

 

Cost of sales

342,268

 

 

342,655

 

 

1,030,427

 

 

1,025,320

 

Gross profit

281,978

 

 

280,233

 

 

858,149

 

 

844,252

 

Selling, general and administrative expenses

128,257

 

 

130,479

 

 

399,237

 

 

406,354

 

Restructuring expenses

11,956

 

 

4,621

 

 

14,082

 

 

8,251

 

Operating income

141,765

 

 

145,133

 

 

444,830

 

 

429,647

 

Other (income) expense - net

1,219

 

 

934

 

 

701

 

 

(3,565

)

Interest expense

11,330

 

 

10,958

 

 

33,262

 

 

33,098

 

Income before income taxes

129,216

 

 

133,241

 

 

410,867

 

 

400,114

 

Provision for income taxes

24,022

 

 

26,889

 

 

82,196

 

 

87,678

 

Net income

$

105,194

 

 

$

106,352

 

 

$

328,671

 

 

$

312,436

 

 

 

 

 

 

 

 

 

Earnings per Common Share:

 

 

 

 

 

 

 

Basic earnings per common share

$

1.39

 

 

$

1.39

 

 

$

4.34

 

 

$

4.07

 

Diluted earnings per common share

$

1.37

 

 

$

1.37

 

 

$

4.30

 

 

$

4.02

 

 

 

 

 

 

 

 

 

Share Data:

 

 

 

 

 

 

 

Basic weighted average common shares outstanding

75,698

 

 

76,562

 

 

75,532

 

 

76,507

 

Diluted weighted average common shares outstanding

76,577

 

 

77,709

 

 

76,415

 

 

77,717

 

IDEX CORPORATION

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

 

 

September 30, 2019

 

December 31, 2018

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

515,985

 

 

$

466,407

 

Receivables - net

317,305

 

 

312,192

 

Inventories

303,494

 

 

279,995

 

Other current assets

53,840

 

 

33,938

 

Total current assets

1,190,624

 

 

1,092,532

 

Property, plant and equipment - net

273,330

 

 

281,220

 

Goodwill and intangible assets

2,165,298

 

 

2,081,282

 

Other noncurrent assets

84,643

 

 

18,823

 

Total assets

$

3,713,895

 

 

$

3,473,857

 

 

 

 

 

Liabilities and shareholders' equity

 

 

 

Current liabilities

 

 

 

Trade accounts payable

$

147,079

 

 

$

143,196

 

Accrued expenses

185,156

 

 

187,536

 

Short-term borrowings

417

 

 

483

 

Dividends payable

38,018

 

 

33,446

 

Total current liabilities

370,670

 

 

364,661

 

Long-term borrowings

848,728

 

 

848,335

 

Other noncurrent liabilities

331,444

 

 

266,221

 

Total liabilities

1,550,842

 

 

1,479,217

 

Shareholders' equity

2,163,053

 

 

1,994,640

 

Total liabilities and shareholders' equity

$

3,713,895

 

 

$

3,473,857

 

IDEX CORPORATION

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

Nine Months Ended
September 30,

 

2019

 

2018

Cash flows from operating activities

 

 

 

Net income

$

328,671

 

 

$

312,436

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Asset impairments

9,680

 

 

 

Depreciation and amortization

29,599

 

 

29,725

 

Amortization of intangible assets

27,747

 

 

29,505

 

Amortization of debt issuance expenses

1,013

 

 

998

 

Share-based compensation expense

20,620

 

 

19,814

 

Deferred income taxes

11,528

 

 

(1,480

)

Non-cash interest expense associated with forward starting swaps

4,737

 

 

4,869

 

Changes in (net of the effect from acquisitions):

 

 

 

Receivables

(2,071

)

 

(34,057

)

Inventories

(16,987

)

 

(27,903

)

Other current assets

(19,186

)

 

7,635

 

Trade accounts payable

2,807

 

 

(4,420

)

Accrued expenses

(23,222

)

 

33

 

Other - net

1,966

 

 

(11,402

)

Net cash flows provided by operating activities

376,902

 

 

325,753

 

Cash flows from investing activities

 

 

 

Purchases of property, plant and equipment

(36,773

)

 

(39,856

)

Purchase of intellectual property

 

 

(4,000

)

Acquisition of businesses, net of cash acquired

(87,180

)

 

(20,205

)

Proceeds from disposal of fixed assets

957

 

 

211

 

Other - net

407

 

 

(1,180

)

Net cash flows used in investing activities

(122,589

)

 

(65,030

)

Cash flows from financing activities

 

 

 

Payments under revolving credit facilities

 

 

(11,128

)

Payments under other long-term borrowings

(49,923

)

 

 

Dividends paid

(109,227

)

 

(94,913

)

Proceeds from stock option exercises

35,595

 

 

26,793

 

Repurchases of common stock

(54,668

)

 

(50,654

)

Shares surrendered for tax withholding

(12,583

)

 

(11,260

)

Settlement of foreign exchange contracts

 

 

6,593

 

Other - net

(1,865

)

 

 

Net cash flows used in financing activities

(192,671

)

 

(134,569

)

Effect of exchange rate changes on cash and cash equivalents

(12,064

)

 

(10,337

)

Net increase in cash

49,578

 

 

115,817

 

Cash and cash equivalents at beginning of year

466,407

 

 

375,950

 

Cash and cash equivalents at end of period

$

515,985

 

 

$

491,767

 

IDEX CORPORATION

Company and Segment Financial Information - Reported

(dollars in thousands)

(unaudited)

 

 

 

Three Months Ended
September 30, (a)

 

Nine Months Ended
September 30, (a)

 

 

 

2019

 

2018

 

2019

 

2018

 

Fluid & Metering Technologies

 

 

 

 

 

 

 

 

Net sales

$

240,861

 

 

$

239,213

 

 

$

729,572

 

 

$

714,346

 

 

Operating income (b)

77,481

 

 

69,755

 

 

223,493

 

 

207,149

 

 

Operating margin

32.2

%

 

29.2

%

 

30.6

%

 

29.0

%

 

EBITDA

$

82,693

 

 

$

74,844

 

 

$

239,534

 

 

$

222,994

 

 

EBITDA margin

34.3

%

 

31.3

%

 

32.8

%

 

31.2

%

 

Depreciation and amortization

$

5,507

 

 

$

5,500

 

 

$

16,653

 

 

$

16,901

 

 

Capital expenditures

3,627

 

 

6,487

 

 

10,207

 

 

15,142

 

 

 

 

 

 

 

 

 

 

 

Health & Science Technologies

 

 

 

 

 

 

 

 

Net sales

$

229,610

 

 

$

222,426

 

 

$

687,153

 

 

$

670,904

 

 

Operating income (b)

40,170

 

 

49,144

 

 

151,087

 

 

153,519

 

 

Operating margin

17.5

%

 

22.1

%

 

22.0

%

 

22.9

%

 

EBITDA

$

49,194

 

 

$

57,745

 

 

$

178,889

 

 

$

184,659

 

 

EBITDA margin

21.4

%

 

26.0

%

 

26.0

%

 

27.5

%

 

Depreciation and amortization

$

10,296

 

 

$

9,381

 

 

$

29,438

 

 

$

30,860

 

 

Capital expenditures

4,984

 

 

8,614

 

 

16,201

 

 

17,296

 

 

 

 

 

 

 

 

 

 

 

Fire & Safety/Diversified Products

 

 

 

 

 

 

 

 

Net sales

$

154,543

 

 

$

161,832

 

 

$

474,745

 

 

$

485,305

 

 

Operating income (b)

41,967

 

 

44,726

 

 

125,909

 

 

130,162

 

 

Operating margin

27.2

%

 

27.6

%

 

26.5

%

 

26.8

%

 

EBITDA

$

45,625

 

 

$

47,925

 

 

$

136,381

 

 

$

144,398

 

 

EBITDA margin

29.5

%

 

29.6

%

 

28.7

%

 

29.8

%

 

Depreciation and amortization

$

3,566

 

 

$

3,541

 

 

$

10,745

 

 

$

10,912

 

 

Capital expenditures

2,257

 

 

3,787

 

 

8,744

 

 

7,232

 

 

 

 

 

 

 

 

 

 

 

Corporate Office and Eliminations

 

 

 

 

 

 

 

 

Intersegment sales eliminations

$

(768

)

 

$

(583

)

 

$

(2,894

)

 

$

(983

)

 

Operating income (b)

(17,853

)

 

(18,492

)

 

(55,659

)

 

(61,183

)

 

EBITDA

(17,443

)

 

(17,709

)

 

(53,329

)

 

(59,609

)

 

Depreciation and amortization

154

 

 

184

 

 

510

 

 

557

 

 

Capital expenditures

163

 

 

 

 

1,621

 

 

186

 

 

 

 

 

 

 

 

 

 

 

Company

 

 

 

 

 

 

 

 

Net sales

$

624,246

 

 

$

622,888

 

 

$

1,888,576

 

 

$

1,869,572

 

 

Operating income

141,765

 

 

145,133

 

 

444,830

 

 

429,647

 

 

Operating margin

22.7

%

 

23.3

%

 

23.6

%

 

23.0

%

 

EBITDA

$

160,069

 

 

$

162,805

 

 

$

501,475

 

 

$

492,442

 

 

EBITDA margin

25.6

%

 

26.1

%

 

26.6

%

 

26.3

%

 

Depreciation and amortization (c)

$

19,523

 

 

$

18,606

 

 

$

57,346

 

 

$

59,230

 

 

Capital expenditures

11,031

 

 

18,888

 

 

36,773

 

 

39,856

 

IDEX CORPORATION

Company and Segment Financial Information - Adjusted

(dollars in thousands)

(unaudited)

 

 

 

Three Months Ended
September 30, (a)

 

Nine Months Ended
September 30, (a)

 

 

 

2019

 

2018

 

2019

 

2018

 

Fluid & Metering Technologies

 

 

 

 

 

 

 

 

Net sales

$

240,861

 

 

$

239,213

 

 

$

729,572

 

 

$

714,346

 

 

Adjusted operating income (b)

77,481

 

 

70,582

 

 

224,423

 

 

208,462

 

 

Adjusted operating margin

32.2

%

 

29.5

%

 

30.8

%

 

29.2

%

 

Adjusted EBITDA

$

82,693

 

 

$

75,671

 

 

$

240,464

 

 

$

224,307

 

 

Adjusted EBITDA margin

34.3

%

 

31.6

%

 

33.0

%

 

31.4

%

 

Depreciation and amortization

$

5,507

 

 

$

5,500

 

 

$

16,653

 

 

$

16,901

 

 

Capital expenditures

3,627

 

 

6,487

 

 

10,207

 

 

15,142

 

 

 

 

 

 

 

 

 

 

 

Health & Science Technologies

 

 

 

 

 

 

 

 

Net sales

$

229,610

 

 

$

222,426

 

 

$

687,153

 

 

$

670,904

 

 

Adjusted operating income (b)

54,706

 

 

52,260

 

 

165,953

 

 

158,817

 

 

Adjusted operating margin

23.8

%

 

23.5

%

 

24.2

%

 

23.7

%

 

Adjusted EBITDA

$

63,730

 

 

$

60,861

 

 

$

193,755

 

 

$

189,957

 

 

Adjusted EBITDA margin

27.8

%

 

27.4

%

 

28.2

%

 

28.3

%

 

Depreciation and amortization

$

10,296

 

 

$

9,381

 

 

$

29,438

 

 

$

30,860

 

 

Capital expenditures

4,984

 

 

8,614

 

 

16,201

 

 

17,296

 

 

 

 

 

 

 

 

 

 

 

Fire & Safety/Diversified Products

 

 

 

 

 

 

 

 

Net sales

$

154,543

 

 

$

161,832

 

 

$

474,745

 

 

$

485,305

 

 

Adjusted operating income (b)

42,071

 

 

44,786

 

 

126,832

 

 

130,589

 

 

Adjusted operating margin

27.2

%

 

27.7

%

 

26.7

%

 

26.9

%

 

Adjusted EBITDA

$

45,729

 

 

$

47,985

 

 

$

137,304

 

 

$

144,825

 

 

Adjusted EBITDA margin

29.6

%

 

29.7

%

 

28.9

%

 

29.8

%

 

Depreciation and amortization

$

3,566

 

 

$

3,541

 

 

$

10,745

 

 

$

10,912

 

 

Capital expenditures

2,257

 

 

3,787

 

 

8,744

 

 

7,232

 

 

 

 

 

 

 

 

 

 

 

Corporate Office and Eliminations

 

 

 

 

 

 

 

 

Intersegment sales eliminations

$

(768

)

 

$

(583

)

 

$

(2,894

)

 

$

(983

)

 

Adjusted operating income (b)

(17,197

)

 

(17,874

)

 

(54,956

)

 

(59,970

)

 

Adjusted EBITDA

(16,787

)

 

(17,091

)

 

(52,626

)

 

(58,396

)

 

Depreciation and amortization

154

 

 

184

 

 

510

 

 

557

 

 

Capital expenditures

163

 

 

 

 

1,621

 

 

186

 

 

 

 

 

 

 

 

 

 

 

Company

 

 

 

 

 

 

 

 

Net sales

$

624,246

 

 

$

622,888

 

 

$

1,888,576

 

 

$

1,869,572

 

 

Adjusted operating income

157,061

 

 

149,754

 

 

462,252

 

 

437,898

 

 

Adjusted operating margin

25.2

%

 

24.0

%

 

24.5

%

 

23.4

%

 

Adjusted EBITDA

$

175,365

 

 

$

167,426

 

 

$

518,897

 

 

$

500,693

 

 

Adjusted EBITDA margin

28.1

%

 

26.9

%

 

27.5

%

 

26.8

%

 

Depreciation and amortization (c)

$

19,523

 

 

$

18,606

 

 

$

57,346

 

 

$

59,230

 

 

Capital expenditures

11,031

 

 

18,888

 

 

36,773

 

 

39,856

 

 

 

 

 

 

 

 

 

 

(a)

Three and nine month data includes the results of Velcora (July 2019) and Finger Lakes Instrumentation (July 2018) in the Health & Science Technologies segment from the date of acquisition.

(b)

Segment operating income excludes unallocated corporate operating expenses which are included in Corporate Office and Eliminations.

(c)

Depreciation and amortization excludes amortization of debt issuance costs.

 

Contacts

Investor Contact:
William K. Grogan
Senior Vice President and Chief Financial Officer
(847) 498-7070

Contacts

Investor Contact:
William K. Grogan
Senior Vice President and Chief Financial Officer
(847) 498-7070